Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

By sjmartinez • June 13, 2023

Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jun 12:ard-2023-223916. doi: 10.1136/ard-2023-223916. Epub ahead of print. PMID: 37308218.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, methotrexate, Publications, Rheumatology, tumor necrosis factor inhibitors

A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study

Debonnaire P, Zwetsloot PP, Pfister R, Llàcer P, Cipriani A, Milani P, Bonderman D, Ohlmeier C, Evers T, Wyss R, Patorno E, Doshi R, Beisel[...]

Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort

Vershel C, Kim S, Gensler LS, Brown MA, Weisman MH, Ishimori ML, Ward M, Reveille JD, Hwang MC. Examining the Interchangeability of Two Different Patient-Reported[...]

An implantable wireless battery-free spatially selective vagus nerve stimulator

Rutkovskis E, Ravagli E, Lancashire HT, Shah Idil A, Thompson N, Perkins JD, Challita R, Hadaya J, Vivekananda U, Ajijola O, Shivkumar K, Miserocchi A,[...]